IMA is a sensitive indicator for early myocardial ischemia, so acute myocardial ischemia can be detected earlier and the relative risk of cardiac events can be predicted earlier. IMA is a biomarker for the diagnosis of acute coronary syndrome (ACS). ACS has the characteristics of rapid onset, rapid change, uneven clinical manifestations and risk, which makes early diagnosis difficult. Traditional biomarkers such as troponin (cTn), myoglobin (Myo), and creatine kinase isoenzyme (ck-mb) are elevated only when myocardial necrosis occurs, but at this time, patients have irreversible pathological damage. Therefore, an early sensitive biochemical index that can reflect myocardial ischemia is urgently needed for early diagnosis, and IMA is a research hotspot in recent years, which opens up a new path for the early diagnosis of ACS. The sensitivity of IMA to myocardial ischemia in ACS patients was 2 times higher than that of ECG and 4 times higher than that of cTn. IMA is a biochemical marker for the detection of ischemia due to coronary artery spasm. IMA is an ischemic marker, not a diagnostic marker for necrosis. IMA can be used not only for the early diagnosis of ACS patients, but for the assessment of coronary events after PCI. IMA value in patients without collateral circulation was significantly higher than that in patients with collateral circulation, and the increase of IMA value was correlated with the severity of lesions. IMA value can be used as a biochemical marker for early identification of acute stroke -- the median number of increasing in the early period of cerebral hemorrhage.

After the albumin binding with cobalt ion in the sample, the chromogenic agent was added to react with the remaining free cobalt ion to produce the red-brown product. The amount of IMA in the sample can be calculated by comparing it with the same ischemic albumin calibrators.